Editorial

Cervical cancer risk with the use of tumour necrosis factor inhibitors in rheumatoid arthritis: to worry or not to worry?
J A Singh

Viewpoint

Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease

Clinical and epidemiological research

Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden
H Wadström, T Friisell, P Syrén, J Askling, on behalf of the ARTIS study group

Clinical and epidemiological research

Endometriosis and the risks of systemic lupus erythematosus and rheumatoid arthritis in the Nurses’ Health Study II
H R Harris, K H Costenbader, F Mu, M Kruskaloff, S Maltzpen, E W Karlson, S A Mismsen

Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
C Charles-Schoeman, C Buermester, P Nash, C A F Zerbini, J H Gabay, L M Li, P Häusermann, U A Walker, EUSTAR coauthors

A psychometric analysis of outcome measures in peripheral spondyloarthritis
M C Tomàs, S Ramiro, D L Beaton, P Mease, J E Parascandola, J H Song, A L Fanger, R Lendrér

Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis?
M de Hooge, R van den Berg, V Natassio-Campin, M Renneke, P van Gastem, K Fagert, R Landré, M van Oosterhout, R Ramonda, T Hutsenga, D van der Heijde

Statin use and mortality in rheumatoid arthritis: a general population-based cohort study
S R Schonfeldt, I Lu, S K Rau, J D Seeger, Y Zhang, H K Chiu

Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching
S Kurok, S Nakayamata, K Nakano, S Hinsa, S Fukuyo, I Miyagawa, K Hanami, K Saito, Y Tanaka

1328 Clinical and MRI responses to etanercept in early non- radiographic axial spondyloarthritis: 48-week results from the EMBARK study
W P Maksymowych, M Dagoakt, D van der Heijde, J Steep, J Braun, G Citera, A van den Bosch, J Logeat, J Wajdula, H Jones, L Marshall, R Benin, R Pedersen, B Vlahos, S Kouk, J E Hotsowski

1336 Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
C Gabay, M Re, M H Hetland, E-AI Hauge, K Pavluha, M Tomol, H Canbas, K Chatzidoumas, G Lukina, D C Nordstrom, E Lu, J Anaia, M V Hernandez, P M C van Boll, R van Vollenhoven, T K Kien

1343 A patient-initiated DMARD self-monitoring service for people with rheumatoid or psoriatic arthritis on methotrexate: a randomised controlled trial
H McKein, M Shipley, A Olaye, S Moore, S Neuman

1350 Outcomes of percutaneous coronary intervention in patients with rheumatoid arthritis and systemic lupus erythematosus: an 11-year nationwide cohort study
C-H Li, W-W Liu, M-J Chien, W-C Lin, Y-J Yang, C-Y Li, L-M Tai

1357 Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis
H Gyger, C Varika, S Bieckman, K Debuscheere, T Vogi, J Roth, M B Drennan, M Lerne, D Feild, C A Cavender, M D Von, J Delangue, P Van den Bosch, D Eerlamp

1363 Hypericiumenia: complications of urine transporter ABCG2 and the fractional renal clearance of urate
D R W Karmanagan, A J Richen-Curen, N Dalbel, L K Stamp, K M Williams, G C Gautham, R O Day, T R Miriamin

1367 Transitions to different patterns of interstitial lung disease in sclerodema with and without treatment
H J Kim, D P Tashbik, D W Gjerse, M S Brown, E Kleerup, S Chu, J G Belperto, M D Roth, A Aman, R Elashoff, C H Tien, D Khanna, J G Goldin

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics. ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors’ institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless specified or determined by law. Acceptance of advertising does not imply endorsement.

Copyright: © 2016 BMJ Publishing Group and the European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission.

ARD is produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics. ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors’ institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless specified or determined by law. Acceptance of advertising does not imply endorsement.

Copyright: © 2016 BMJ Publishing Group and the European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission.

ARD is produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics. ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors’ institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless specified or determined by law. Acceptance of advertising does not imply endorsement.

Copyright: © 2016 BMJ Publishing Group and the European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission.

ARD is produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics. ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors’ institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless specified or determined by law. Acceptance of advertising does not imply endorsement.

Copyright: © 2016 BMJ Publishing Group and the European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission.

ARD is produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics. ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors’ institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless specified or determined by law. Acceptance of advertising does not imply endorsement.

Copyright: © 2016 BMJ Publishing Group and the European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission.
Basic and translational research

1372 Interleukin-6 and chondrocyte mineralisation act in tandem to promote experimental osteoarthritis
S Nasi, A So, C Combes, M Daudon, N Busso

1380 Whole-genome single nucleotide polymorphism-based linkage analysis in spondyloarthritis multiplex families reveals a new susceptibility locus in 13q13
P Costantino, E Chaplain, T Leturcq, R Sastri-Nathal, A Lebre, E Zouini, D Zelentza, I Cox, C Charon, C Chocquita, M Breban, H-J Carchon

1386 MICL controls inflammation in rheumatoid arthritis

1392 Acute serum amyloid A is an endogenous TLR2 ligand that mediates inflammatory and angiogenic mechanisms
M Connolly, P R Rooney, T McGarry, A X Maratha, J McCormick, S M Miggin, D J Veale, U Fearon

1399 Efficient therapy of ischaemic lesions with VEGF121-fibrin in an animal model of systemic sclerosis
S A Bignetti, M Mallender, I Weste, H Dietrich, J Gruber, O Distler, R Sgonc

1407 Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus

Electronic pages

1417 Replication of a distinct psoriatic arthritis risk variant at the IL23R locus

Letters

1418 Evidence of response to IL-6 inhibition in some cases of refractory spondyloarthritis-associated peripheral synovitis
M Matsuki, G De Marco, M Pendezzi, D McGonagle, H Marzo-Orgiza

1420 Negative association between autoantibodies against IL-17, IL-17/anti-IL-17 antibody immune complexes and destruction in rheumatoid arthritis
N Ndongo-Thiam, A Clement, J-J Pin, D Rezaei-Razavi, P Alievic

Miscellaneous

1422 Corrections